Friday, July 14, 2017 News Recap Local New measures boost addiction treatment access in Victoria New efforts to expand treatment for opioid users in Victoria are putting addiction specialists in hospital emergency departments and supporting family doctors who provide opioid substitution therapy for patients. The initiatives by Island Health and the Victoria Divisions of Family Practice are intended to dovetail with the work of the South Island Ra...
HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining the use of Spring Bank's oral selective immunomodulator, SB 9200, co-administered with Gilea
MISSISSAUGA, ON, June 19, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for VEMLIDY™ (tenofovir alafenamide, TAF) 25mg tablets, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. – VEMLIDY is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters C
An estimated 325 million people are living with hepatitis B or C and few are aware of their condition, with death tolls from the viruses rising, the UN said Friday. The World Health Organization's latest hepatitis report identifies the condition as a grave public health threat that needs an "urgent response." Hepatitis killed 1.34 million people in 2015, a toll roughly in-line with HIV and tuberculosis. But in contrast to HIV and TB, hepatitis death
Survival rates are rising but more than 1,000 people die every year in Ontario from liver cancer. Liver cancer is to blame for more than a thousand deaths every year in Ontario — and most of these occur in the Greater Toronto Area. In fact, the epidemic level of liver cancer in this city often goes unrecognized, as it’s diluted by provincial and national statistics. So what is it about Toronto that makes it such a hot spot for this type of cancer? M
Vemlidy is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters Compared to Viread FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated li
It is possible to end the transmission of hepatitis B and C and prevent further sickness and deaths from the diseases, but time, considerable resources, and attention to various barriers will be required, says a new report from the National Academies of Sciences, Engineering, and Medicine. However, controlling the diseases by reducing the number of new and overall cases in the U.S. is more feasible in the short term. This is the first report of a two-phase
The most current statistics, research, and data about hepatitis B and C, as well as other liver diseases, can be found in the recent report, Liver Disease in Canada: A Crisis in the Making: An Assessment of Liver Disease in Canada Published by the Canadian Liver Foundation in March, 2013. Dr. Morris Sherman (MB.BCh, PhD, FRCP(C)), et al. Download this ENTIRE important report in PDF format from:http://www.liver.ca/files/PDF/Liver_Disease_Report_2013/Liver_D